Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2 in Healthy Volunteers

The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2

pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2

Inclusion Criteria:

• Male or female adults aged 19-45 years.
• BMI of >18.5 kg/㎡ and <27.0 kg/㎡ subject, weight more than 50kg.
• Voluntarily provided a witten consent to participate in this clinical study.

Exclusion Criteria:

• Treatment with an investigational product (Phase I study or Biological study) within 3month preceeding the first dose of study medication.
• History of (or presence) study medication absortion, distribution, metabolism(e.g., liver/ductal, kidney, cardio-vascular, endocrine, respiratory, GI, hematology, oncology, CNS, musculo-skeletal) or related past medical/surgery history
• Pregnant or lactating women.